Guardant Health, Inc. (NASDAQ:GH) Director Sells $81,200.00 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Guardant Health Trading Down 7.1 %

Shares of GH opened at $32.36 on Thursday. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $38.53. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of -7.63 and a beta of 1.26. The firm has a 50 day simple moving average of $28.48 and a 200-day simple moving average of $28.27.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $191.48 million for the quarter, compared to analysts’ expectations of $170.49 million. During the same period in the previous year, the business posted ($0.73) EPS. The business’s quarterly revenue was up 33.9% on a year-over-year basis. Equities analysts forecast that Guardant Health, Inc. will post -3.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. JNBA Financial Advisors purchased a new stake in Guardant Health in the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Guardant Health during the third quarter worth $34,000. Quarry LP purchased a new stake in shares of Guardant Health in the second quarter valued at $44,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Guardant Health in the second quarter valued at $71,000. Finally, Byrne Asset Management LLC purchased a new position in Guardant Health during the second quarter worth about $77,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on GH shares. Sanford C. Bernstein reduced their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. The Goldman Sachs Group upped their price target on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Leerink Partners reduced their price objective on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, UBS Group boosted their price objective on shares of Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 21st. Fifteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.